Curis, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Curis, Inc. now
Current reporting with the operating signal separated from the noise.
Curis, Inc.: Curis Doses First Five Patients in TakeAim CLL Study
The development tests whether Curis, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript
Investors are testing whether Curis, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest CRIS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Curis, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →